Amicus Therapeutics, Inc
FOLDAmicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic disorders. They specialize in protein misfolding diseases, utilizing both small molecule chaperones and gene therapy approaches to treat conditions such as Fabry disease, Pompe disease, and other lysosomal storage disorders. The company aims to leverage innovative science to address unmet medical needs in the rare disease community.
Company News
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures, and is offering contingent fee representation.
Law firm Brodsky & Smith has initiated investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Clearwater Analytics ($24.55/share), Katapult Holdings (6% ownership in combined entity), Janu...
BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $4.8 billion on Friday. The acquisition is expected to accelerate revenue growth and be accretive to earnings within 12 months. Analysts view the deal favorably, with Truist Securities raising its price target from $80 to $100. The acquisition adds two revenue-generating rare disea...
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.
